The Brunner Investment Trust PLC Annual Report for the year ended 30 November 2022
selection, with long-term portfolio performance
similarly driven by the individual returns of each
company.
The portfolio’s biggest contributor to returns
this year was UnitedHealth Group. Shares in
the US-based provider of health insurance
have benefited from investors seeking more
defensive positions. However, the underlying
business has also continued to be strong.
Successive quarters of above-guidance revenue
growth have enabled the company to raise
its full year EPS guidance, thanks in large
part to the strength of its Optum healthcare
services division. Looking forward to next year,
UnitedHealth is as conservative as ever, guiding
for 12% EPS growth – a range it has typically
beaten. While the shares have performed well
this year, they remain on a reasonable long-
term valuation and the position continues to be
a key holding.
Other strong contributors within Health Care
included Abbvie and Novo Nordisk. While
both are pharmaceutical giants, Abbvie
specialises in blockbuster drugs – its most
famous being the anti-inflammatory Humira
which faces a patent cliff in 2023. Shares in
Abbvie have rallied as weakness in Humira has
been lower than expected, while at the same
time the commercial performance of its Skyrizi
psoriasis treatment has also surprised positively.
Given the potential impact of biosimilars on
Humira in 2023, the near-term outlook remains
unclear. However, with its acquisition of Allergan
in 2020, Abbvie has given itself a sizeable
source of recurring revenue to underpin its
future pipeline. Currently trading at around
11x next year’s earnings and with a dividend
yield of over 3.5%, we are comfortable with our
relatively small position.
Novo Nordisk, by contrast, provides long-lasting
treatment for obesity-related illnesses such
as diabetes. Like UnitedHealth, the business
model is less geared to the global economy,
and this has supported its valuation. At the
same time, the reopening of doctors’ practices
has re-enabled Novo to sign on new patients.
This has been particularly beneficial for the
rollout of Novo’s GLP-1 product Wegovy,
for obesity, which helps to regulate insulin
production and glucose release within the body.
After its Q3 results, the company raised full
year sales guidance by 2%, bringing expected
revenue growth and EPS to 25% and 16%,
respectively. Longer-term growth continues to
be underpinned by international markets, which
are seeing a transition from older to newer
products as well as rising demand for diabetes-
adjacent medication.
Outside of Health Care, the portfolio has also
benefited from its position in Visa. Despite the
positive overall contribution, shares in the digital
payments company have proved volatile due
to a range of divergent narratives. On the one
hand, an increase in economic activity post-
pandemic and in particular international
travel, is providing a strong boost to both
topline and margins. Indeed, full year revenues
and net income are expected to grow 22% and
26% respectively, compared to 10% and 16%
last year.
Yet the shares have also struggled in the face of
inflation, with investors fearing softer economic
activity in the medium-term, and potential
disruption from alternative providers. These
appear overdone. Visa’s status as the network
provider for payments, rather than a creditor,
means it captures inflation as a benefit. At the
same time, the company continues to harness
a growing network effect thanks to relatively
small transaction costs, a high user base but
room for further digital payment penetration.
Lastly, we have also benefited from our position
in Homeserve. The company is a UK-listed
provider of domestic maintenance insurance
and related services, with sizeable international
operations. Our original investment case
was predicated on the steady growth in
Homeserve’s core insurance business, as well as
the – for valuation purposes – optional upside
of the online Checkatrade comparison site.
However, in May, the company announced
that it would be sold to Brookfield, a Canadian
private equity company at a premium of c.71%
to its share price.
In recent years, buyouts of quality UK
companies have become a recurring feature of
the investment landscape. The combined effect
of Brexit, turbulent politics and an initially poor
approach to the Covid-19 pandemic has left
the UK market as a whole trading at a discount.
As a result, many high-quality companies, often
with strong growth, trade at far lower valuations
than if they were to be listed in other markets.
In the past five years, we have seen held
companies like UBM, Stock Spirits Group and
Homeserve all taken off the market by either
private equity or peers.
Weakness in the portfolio has been similarly
driven by a combination of macro headwinds
and idiosyncratic stock performance. Some of
the portfolio’s largest detractors are linked to
consumer weakness, although not all of them
fit neatly into the Consumer Discretionary
sector. Similarly, our preference for Financials
stocks which generate returns through fees
28